{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:18:39Z","timestamp":1740460719887,"version":"3.37.3"},"reference-count":20,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2023,3,12]]},"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1183\/13993003.00346-2023","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:35:44Z","timestamp":1683282944000},"page":"2300346","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The art of clinical trial design in pulmonary fibrosis"],"prefix":"10.1183","volume":"61","author":[{"given":"J\u00fcrgen","family":"Behr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"2024102012262508000_61.5.2300346.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02163-2022"},{"key":"2024102012262508000_61.5.2300346.2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12931-019-1021-2","article-title":"Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis","volume":"20","author":"Costabel","year":"2019","journal-title":"Respir Res"},{"key":"2024102012262508000_61.5.2300346.3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan","year":"2019","journal-title":"Respir Med"},{"key":"2024102012262508000_61.5.2300346.4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2024102012262508000_61.5.2300346.5","doi-asserted-by":"publisher","DOI":"10.1159\/000518855"},{"key":"2024102012262508000_61.5.2300346.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208819"},{"key":"2024102012262508000_61.5.2300346.7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102012262508000_61.5.2300346.8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-018-0866-0","article-title":"Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS\u00ae trials","volume":"19","author":"Costabel","year":"2018","journal-title":"Respir Res"},{"key":"2024102012262508000_61.5.2300346.9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000486286","article-title":"Statin therapy and outcomes in trials of nintedanib in idiopathic pulmonary fibrosis","volume":"95","author":"Kreuter","year":"2018","journal-title":"Respiration"},{"key":"2024102012262508000_61.5.2300346.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208710"},{"key":"2024102012262508000_61.5.2300346.11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102012262508000_61.5.2300346.12","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0845-5"},{"key":"2024102012262508000_61.5.2300346.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02279-2019"},{"key":"2024102012262508000_61.5.2300346.14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.arbres.2022.04.007","article-title":"Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): clinical characteristics, evolution and treatment","volume":"58","author":"Caro","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2024102012262508000_61.5.2300346.15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/resp.14116","article-title":"Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort","volume":"26","author":"Durheim","year":"2021","journal-title":"Respirology"},{"key":"2024102012262508000_61.5.2300346.16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12931-019-0977-2","article-title":"Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry","volume":"20","author":"Zurkova","year":"2019","journal-title":"Respir Res"},{"key":"2024102012262508000_61.5.2300346.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2024102012262508000_61.5.2300346.18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102012262508000_61.5.2300346.19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102012262508000_61.5.2300346.20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00346-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:14:11Z","timestamp":1740381251000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00346-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1183\/13993003.00346-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00346-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"type":"print","value":"0903-1936"},{"type":"electronic","value":"1399-3003"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}